“Baiyingnuo Technology” completed seed round financing of over 10 million yuan to accelerate product pipeline research and development


Visit the original URL

Chuangyebang was informed that recently, Wuhan Baiyingnuo Biotechnology Co., Ltd. (hereinafter referred to as “Baiyingnuo Technology”) announced the completion of a tens of millions of seed round financing. This financing was jointly invested by Dongke Chuangxing and Wuhan Biotechnology Research Institute. The funds obtained from the financing will be used to promote the research and development and registration inspection of various product pipelines of Bioinno Technology, so as to accelerate the launch of product pipelines and the acquisition of IND clinical approval documents.

Founded in June 2021, Bioinno Technology is committed to the screening and verification of new cancer immunotherapy sites, preclinical research on antibody drugs and cell therapy drugs, and provides advanced immunotherapy diagnosis and services for tumors. At the same time, it is also actively Deploy peptide drug research and development. In January 2022, the company signed a scientific research cooperation agreement with Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology to promote the smooth implementation of cooperation projects and the transformation of potential achievements.

At present, the company has gathered a large number of experts, professors and industrialization teams from the fields of oncology, immunology and medical testing. In the technical team, 6 people have doctoral degrees, 5 people have overseas study experience, and 4 people are selected into the national high-level talent plan. At present, Bioinno Technology has established the only team in China with the original innovation capability of cancer companion diagnosis.

Based on the current status of malignant tumor treatment and the needs of patients, Bioinno Technology has independently developed two core products. Among them, the PD-L1 companion diagnostic kit “Innokang” greatly improves the detection specificity on the basis of maintaining a high detection sensitivity, so that patients with advanced cancer can be diagnosed more accurately, and thus have the hope of cure. The new anti-tumor cell metastasis polypeptide drug “Innotex” can fundamentally control the problem of pleural and ascites by inhibiting the activity and metastasis of cancer cells, and prolong the life cycle of patients with advanced cancer.

By inhibiting the activity and metastasis of cancer cells, the new peptide drug “Innovate” independently developed by Bioinno can fundamentally control pleural and ascites, prolong the life cycle of patients with advanced cancer, relieve the pain of patients and improve the quality of life.

Li Runqing, general manager of Bioinnovation, said: “Since the establishment of the company, Bioinnovation has been committed to transforming clinically proven technological innovations into industrial achievements in precision immunotherapy, so that patients with advanced cancer still have hope of cure. In the future, we will It will also continue to focus on the needs of cancer diagnosis and treatment, practice the concept of precision treatment, and help the development of human health.”

Zhu Zifang, founder and general manager of Dongke Chuangxing, believes: “With the trend of population aging, the number of new cancers in China continues to grow. In recent years, more and more cancer indications have been approved, and more and more immunotherapy drugs have been shortlisted. With the medical insurance catalog, Bioinno Technology is expected to take advantage of this wind and enter the fast lane of development. With the completion of this round of financing, Bioinno Technology will also contribute more to the cause of human health.”

media coverage

Yiou investment community entrepreneurial state
Related events

This article is reproduced from: https://readhub.cn/topic/8io44Sxh0M1
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment